December 7, 2021
The University of Cincinnati's Dr. Vladimir Bogdanov has been awarded a Catalyst Research Award to further investigate if a drug he and his team developed is effective in treating pancreatic cancer.
January 20, 2022
University of Cincinnati researcher physicians are hosting the BEAT-MS trial which will study the effectiveness of stem cell transplant compared to the currently best available treatments for multiple sclerosis.
January 13, 2022
University of Cincinnati researchers have received a U.S. Department of Defense grant to further study how stress hormone receptors affect brain cell degeneration in Parkinson's disease.
August 15, 2022
Drs Melanie Cushion, Michael Farrell and Bruce Giffin have been named 2022 recipients of Daniel Drake Medals.
September 6, 2022
University of Cincinnati and Cincinnati Children's Hospital Medical Center researchers published new findings on metabolic signatures that help predict breast cancer outcomes and could open avenues for new treatments in the journal PLOS ONE.
September 7, 2022
University of Cincinnati researchers recently published study results in JAMA Otolaryngology showing that administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer did not increase rates of complication during and after surgery.
April 11, 2023
The University of Cincinnati's Atsuo Sasaki, PhD, is leading a multidisciplinary team that received National Institutes of Health funding to learn more about how an enzyme that was previously overlooked helps regulate lysosome and cellular function.
April 19, 2023
The University of Cincinnati is one of 50 nationwide trial sites for a new clinical trial testing a new treatment for status epilepticus, the most severe and deadly form of epilepsy.
May 19, 2023
The University of Cincinnati Cancer Center's Syed Ahmad, MD, is the national principal investigator for a phase 2 trial testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
October 24, 2022
University of Cincinnati researchers presented results from the first-in-human trial of FLASH radiotherapy at the ASTRO 2022 annual meeting, with data suggesting FLASH may hold promise as a potential treatment for tough-to-kill tumors.